Introduction: As biosimilars become available in the market to potentially lower costs of inflammatory conditions and ease patient access to highly effective and targeted therapies, NPs can help ensure that patients have access to necessary education and to be a part of their care. As front-line providers, NPs are in a unique position to educate patients on the adoption of biosimilars. Patients will look to NPs as patient advocates to answer their questions regarding the safety and efficacy of biosimilar agents. This educational activity focused on education to ensure that NPs have the tools to answer their patients’ questions and guide the successful transition and utilization of biosimilar agents.

Biosimilars are a class of medication approved by the FDA. NPs may be unfamiliar with the concept of biosimilars in relation to their originator drug. NPs require up-to-date targeted education related to appropriately selecting patients who will benefit from switching from originator drugs to biosimilars.

As front-line providers, NPs are uniquely positioned to provide patients with the most up-to-date information regarding the safety and efficacy of biosimilars. When patient education is conducted with NPs, patients with educational sessions to ensure patients are comfortable with their management.

Learner Demographics and Engagement

<table>
<thead>
<tr>
<th>Learners</th>
<th>Certificates</th>
<th>8.813</th>
</tr>
</thead>
</table>

Changes in Knowledge

- Knowledge of the structure of biosimilar: 4.6/5 average
- Knowledge of the 2020 pathway for the FDA biosimilar development: 4.7/5 average
- Knowledge in the efficacy and safety of biosimilar when switching from originator product: 4.6/5 average 

60-Day Follow-up (n=99)

- Over the past 60 days, I have identified one or more patients who were a candidate for switching from a biologic to a biosimilar (n=79)
- Over the past 60 days have you used the information from this activity for any of the following? (n=78)

Changes in Confidence

- Knowledge in the efficacy and safety of switching from a biologic to a biosimilar (n=78)

Future Educational Needs

- Biosimilar development focus
- Officers and safety of switching between biosimilars of same reference product

Program Information & Methods

- Programs: Training occurred through an accredited monograph hosted on-demand. One uncredited produc was produced and hosted on AANP’s platform - NP Pulse: The Value of the Nurse-Practitioner
- Data Collected: Changes in knowledge, competence, self-reported changes in confidence and practice habits, and identification of remaining gaps.

Measurements and analysis: Questions were asked before and immediately after the activity. A 60-day follow-up survey was sent to participants who completed the activity to identify any practice changes made.

Demographics (pre), evaluation (post), and follow-up survey results shown here use descriptive statistics.

- Tests used to identify statistically significant differences pre to post:
  - McNemar test for each of 10 multiple-choice knowledge/case questions
  - Wilcoxon test for 4 correct knowledge/case questions, and the confidence rating scale questions.

- P ≤ 0.05 indicates a statistically significant difference.

- Effect Size (ES), to indicate the size of the change, was also calculated as appropriate. (Cohen’s d: 0.20 = small, 0.50 = medium, 0.80 = large).

Results

- Changes in knowledge: n=6,506 paired data, P<0.001

- Results

- 60-Day Follow-up (n=99)

- Over the past 60 days, how many patients did you see who were a candidate for switching from a biologic to a biosimilar? (n=79)

- Over the past 60 days, have you used the information from this activity for any of the following? (n=78)

- Over the past 60 days, I have identified one or more patients who were a candidate for switching from a biologic to a biosimilar (n=79)

- Over the past 60 days, I have taken the opportunity to discuss biosimilars with one or more patients (n=79)

- Over the past 60 days, I have started one or more patients on a biosimilar (n=79)

- Over the past 60 days, I have switched one or more patients from a biologic to a biosimilar (n=79)

- Over the past 60 days, I have referred one or more patients to a rheumatologist (n=79)

- Over the past 60 days, I have taken the opportunity to discuss biosimilars with one or more patients (n=79)

- Over the past 60 days, I have started one or more patients on a biosimilar (n=79)

- Over the past 60 days, I have switched one or more patients from a biologic to a biosimilar (n=79)

- Over the past 60 days, I have referred one or more patients to a rheumatologist (n=79)